These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 39408940)

  • 21. Therapeutic interventions for gut dysbiosis and related disorders in the elderly: antibiotics, probiotics or faecal microbiota transplantation?
    Vemuri RC; Gundamaraju R; Shinde T; Eri R
    Benef Microbes; 2017 Apr; 8(2):179-192. PubMed ID: 28008784
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bifidobacterium reduction is associated with high blood pressure in children with type 1 diabetes mellitus.
    Lakshmanan AP; Shatat IF; Zaidan S; Jacob S; Bangarusamy DK; Al-Abduljabbar S; Al-Khalaf F; Petroviski G; Terranegra A
    Biomed Pharmacother; 2021 Aug; 140():111736. PubMed ID: 34034069
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anorexia nervosa and gut microbiome: implications for weight change and novel treatments.
    Wei Y; Peng S; Lian C; Kang Q; Chen J
    Expert Rev Gastroenterol Hepatol; 2022 Apr; 16(4):321-332. PubMed ID: 35303781
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic potential of probiotics in gut microbial homeostasis and Rheumatoid arthritis.
    Balasundaram D; Veerasamy V; Sylvia Singarayar M; Neethirajan V; Ananth Devanesan A; Thilagar S
    Int Immunopharmacol; 2024 Aug; 137():112501. PubMed ID: 38885604
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Understanding how pre- and probiotics affect the gut microbiome and metabolic health.
    Bock PM; Martins AF; Schaan BD
    Am J Physiol Endocrinol Metab; 2024 Jul; 327(1):E89-E102. PubMed ID: 38809510
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gut Microbiome in Alzheimer's Disease: from Mice to Humans.
    Liang C; Pereira R; Zhang Y; Rojas OL
    Curr Neuropharmacol; 2024; 22(14):2314-2329. PubMed ID: 39403057
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting the gut microbiota and its metabolites for type 2 diabetes mellitus.
    Wu J; Yang K; Fan H; Wei M; Xiong Q
    Front Endocrinol (Lausanne); 2023; 14():1114424. PubMed ID: 37229456
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synbiotics, prebiotics and probiotics for solid organ transplant recipients.
    Cooper TE; Scholes-Robertson N; Craig JC; Hawley CM; Howell M; Johnson DW; Teixeira-Pinto A; Jaure A; Wong G
    Cochrane Database Syst Rev; 2022 Sep; 9(9):CD014804. PubMed ID: 36126902
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gut Microbiota: An Important Player in Type 2 Diabetes Mellitus.
    Zhou Z; Sun B; Yu D; Zhu C
    Front Cell Infect Microbiol; 2022; 12():834485. PubMed ID: 35242721
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of microbiome therapy on COVID-19-induced gut dysbiosis: A narrative and systematic review.
    Yousef M; Rob M; Varghese S; Rao S; Zamir F; Paul P; Chaari A
    Life Sci; 2024 Apr; 342():122535. PubMed ID: 38408636
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gut microbiota dysbiosis and its impact on asthma and other lung diseases: potential therapeutic approaches.
    Kim YC; Sohn KH; Kang HR
    Korean J Intern Med; 2024 Sep; 39(5):746-758. PubMed ID: 39252487
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gut microbiota as the critical correlation of polycystic ovary syndrome and type 2 diabetes mellitus.
    Duan L; An X; Zhang Y; Jin D; Zhao S; Zhou R; Duan Y; Zhang Y; Liu X; Lian F
    Biomed Pharmacother; 2021 Oct; 142():112094. PubMed ID: 34449321
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic microbiome modulation: new frontiers in HIV treatment.
    Bulnes R; Utay NS
    Curr Opin HIV AIDS; 2024 Sep; 19(5):268-275. PubMed ID: 38874442
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diabetes and the Gut Microbiome.
    Lau WL; Tran T; Rhee CM; Kalantar-Zadeh K; Vaziri ND
    Semin Nephrol; 2021 Mar; 41(2):104-113. PubMed ID: 34140089
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Distinctive Microbial Signatures and Gut-Brain Crosstalk in Pediatric Patients with Coeliac Disease and Type 1 Diabetes Mellitus.
    Singh P; Rawat A; Al-Jarrah B; Saraswathi S; Gad H; Elawad M; Hussain K; Hendaus MA; Al-Masri W; A Malik R; Al Khodor S; Akobeng AK
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33546364
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Periodontal treatment and microbiome-targeted therapy in management of periodontitis-related nonalcoholic fatty liver disease with oral and gut dysbiosis.
    Kuraji R; Shiba T; Dong TS; Numabe Y; Kapila YL
    World J Gastroenterol; 2023 Feb; 29(6):967-996. PubMed ID: 36844143
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gut microbiome-targeted therapies for Alzheimer's disease.
    Zhang T; Gao G; Kwok LY; Sun Z
    Gut Microbes; 2023 Dec; 15(2):2271613. PubMed ID: 37934614
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-alcoholic fatty liver disease and gut microbial dysbiosis- underlying mechanisms and gut microbiota mediated treatment strategies.
    Jayachandran M; Qu S
    Rev Endocr Metab Disord; 2023 Dec; 24(6):1189-1204. PubMed ID: 37840104
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Insights into Gut Dysbiosis: Inflammatory Diseases, Obesity, and Restoration Approaches.
    Acevedo-Román A; Pagán-Zayas N; Velázquez-Rivera LI; Torres-Ventura AC; Godoy-Vitorino F
    Int J Mol Sci; 2024 Sep; 25(17):. PubMed ID: 39273662
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Physiological patterns of intestinal microbiota. The role of dysbacteriosis in obesity, insulin resistance, diabetes and metabolic syndrome].
    Halmos T; Suba I
    Orv Hetil; 2016 Jan; 157(1):13-22. PubMed ID: 26708682
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.